Akebia Therapeutics (AKBA) EPS (Basic) Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.18% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.42% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 12.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -35.06% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.47% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 17.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.94% |
| Mar 31, 2026 | 38.46% |
| Dec 31, 2025 | -28.27% |
| Sep 30, 2025 | 26.14% |
| Jun 30, 2025 | -81.97% |
| Mar 31, 2025 | 27.51% |
| Dec 31, 2024 | 35.91% |
| Sep 30, 2024 | 34.73% |
| Jun 30, 2024 | 57.00% |
| Mar 31, 2024 | 41.56% |
| Dec 31, 2023 | 26.10% |
| Sep 30, 2023 | 43.13% |
| Jun 30, 2023 | 64.02% |
| Mar 31, 2023 | 32.51% |
| Dec 31, 2022 | 69.00% |
| Sep 30, 2022 | 13.79% |
| Jun 30, 2022 | 32.50% |
| Mar 31, 2022 | 17.01% |
| Dec 31, 2021 | 26.52% |
| Sep 30, 2021 | 9.14% |